Abalone Bio develops target-activating antibodies using its Functional Antibody Selection Technology (FAST) platform, which enables the rapid identification of antibody activators for challenging G-protein coupled receptors (GPCRs). This approach addresses the lack of effective therapeutics for key disease targets, providing a solution to the specificity issues associated with existing small molecule drugs.
Funding
$1.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AV+1Founders
Product
Problem
Many key disease targets lack effective therapeutics, leaving millions of patients untreated. Existing small molecule drugs often have off-target interactions, resulting in intolerable side effects due to a lack of specificity. While antibodies offer specificity, it has been challenging to discover antibodies that can activate certain targets.
Solution
Abalone Bio develops target-activating antibodies using its Functional Antibody Selection Technology (FAST) platform. This platform enables the rapid creation of antibody activators, particularly for challenging G-protein coupled receptors (GPCRs). The FAST platform measures antibody function, not just binding, by testing hundreds of millions of antibodies in parallel. Abalone Bio's approach has enabled AI to predict activating antibodies, and the company has already created activating antibodies for multiple GPCRs.
Target Audience
Abalone Bio's primary customers are pharmaceutical companies seeking target-activating antibodies for their key targets, as well as researchers focused on developing novel therapeutics for diseases impacting millions of lives.
Features
- Functional Antibody Selection Technology (FAST) platform for rapid discovery of activating antibodies
- Focus on challenging targets, particularly GPCRs, which regulate nearly every biological area
- Massively parallel screening of 100M antibodies at once, measuring function not just binding
- Engineered yeast cells that link cell survival to antibody function against a target
- Proprietary activity datasets that enable AI-guided antibody design
- Ability to create activating antibodies for targets where few or no such antibodies exist